Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vanda Pharmaceuticals 2200 PENNSYLVANIA AVENUE NW SUITE 300E WASHINGTON DC 20037 USA

P: 202-734-3400 F: 202-296-1450

Description:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Key Statistics

Overview:

Market Capitalization, $K 892,328
Shares Outstanding, K 53,337
Annual Sales, $ 193,120 K
Annual Net Income, $ 25,210 K
Last Quarter Sales, $ 59,490 K
Last Quarter Net Income, $ 100,420 K
60-Month Beta 0.35
% of Insider Shareholders 8.20%
% of Institutional Shareholders 99.29%
Float, K 48,963
% Float 91.80%

Growth:

1-Year Return -36.02%
3-Year Return 4.89%
5-Year Return 36.57%
5-Year Revenue Growth 470.01%
5-Year Earnings Growth 171.64%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.84 on 11/06/19
Next Earnings Date N/A
Earnings Per Share ttm 2.23
EPS Growth vs. Prev Qtr 776.19%
EPS Growth vs. Prev Year 1,315.38%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 05/07/09

VNDA Ratios

Ratio
Price/Earnings ttm 7.61
Price/Earnings forward -1,142.00
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) 38.90
Return-on-Assets (Before Tax) 31.81
Profit Margin % 13.05
Net Margin % 14.19
Debt/Equity 0.00
Price/Sales 4.69
Price/Cash Flow 31.63
Price/Book 2.26
Book Value/Share 7.53
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar